- Active Pharmaceutical Ingredients
- Varenicline tartrate
- Aprepitant, Fosapitant Intermediates
- Fosaprepitant Dimeglumine
- Vildagliptin
- Efinaconazole
- Luliconazole Intermediate
- Gadoterate Meglumine
- Succinyl Alcohol Intermediate
- Mirabillon Intermediate
- Atazanavir Intermediate
- Intermediate
- Varenicline tartrate 230615-70-0
- Aprepitant 287930-73-8
- Aprepitant 127852-28-2
- Aprepitant 287930-75-0
- Aprepitant 200000-59-5
- Aprepitant 155742-64-6
- Aprepitant 252742-72-6
- Fosaprepitant Dimeglumine 990-91-0
- Fosaprepitant Dimeglumine 265121-01-5
- Vildagliptin 207557-35-5
- Vildagliptin 702-82-9
- Efinaconazole 144230-50-2
- Efinaconazole 133775-25-4
- Efinaconazole 127000-90-2
- Gadoterate Meglumine
- Mirabegron
- Luliconazole 98873-55-3
- Luliconazole 126534-31-4
- Atazanavir sulfate
- Bortezomib 179324-87-9
- Bortezomib 114457-94-2
- Bortezomib 205393-22-2
- Brinzolamide
- Rivaroxaban Intermediate 446292-08-6
- Rivaroxaban Intermediate 446292-07-5
- Cinacalcet Hydrochloride 1005450-55-4
- Cinacalcet Hydrochloride 585-50-2
- Eletriptan Intermediate
- Indacaterol intermediate 312753-53-0
- Indacaterol intermediate 173140-90-4
- Sitagliptin Intermediate
- Fosanavir Calcium Intermediate
Popular information
Vintagliptin intermediate
【Catalog Number】AP2705
【CAS #】207557-35-5
【Molecular Formula】C7H9ClN2O
【Molecular Weight】172.61
|
Alias |
Vinitaliptin Intermediate |
|
Catalog Number |
AP2705 |
|
CAS # |
207557-35-5 |
|
Molecular Formula |
C7H9ClN2O |
|
Molecular Weight |
172.61 |
|
Structural Formula |
 |
|
Product Introduction CAS 207557-35-5 |
(2S) -N-chloroacetyl-2-cyanotetrahydropyrrole, the English name is (2S) -1- (Chloroacetyl) -2- pyrrolidinecarbonitrile, U.S. Chemical Abstracts Registry No. cas 207557-35-5. (2S) -N-chloroacetyl-2-cyanotetrahydropyrrole (CAS 207557-35-5) is an intermediate of vidagliptin. Vidagliptin is a selective, competitive, and reversible DPP_4 inhibitor. By combining with DPP-4 to form a DPP-4 complex to inhibit the activity of the enzyme, while increasing the concentration of GLP-1 and promoting the production of insulin by islet B cells, it also lowers the concentration of glucagon, thereby reducing blood glucose, and has no effect on body weight. Significant impact. This product is an oral anti-diabetic drug. |
VIWIT 沪ICP备12014533号-2
